Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 24 of 30
Mar 6, 2026As biotech companies accelerate clinical programs to achieve competitive and regulatory milestones, workforce adjustments often follow. Alltrna’s recent announcement of laying off over a third of its staff signals a critical phase in its development strategy, underscoring the balancing act between advancing pipelines and maintaining operational efficiency.
Mar 6, 2026Eli Lilly has launched Lilly Employer Connect, a platform aimed at providing employers with more flexible access to treating obesity through drugs such as Zepbound. While the platform introduces practical options for employers, industry experts note that the progress is largely incremental rather than transformative. This post explores the platform, its features, and the implications for employers and the obesity treatment landscape.
Mar 5, 2026South Korea has become an increasingly attractive destination for pharmaceutical companies due to its expertise in cutting-edge therapeutic modalities. Roche’s recent pledge underscores this trend, fueling expanded clinical research and investment in the region’s biopharma ecosystem.
Mar 5, 2026Emerging research links GLP-1 receptor agonists to a decreased incidence of addictive behavior consequences, suggesting a potential role for these drugs beyond metabolic disorders. The implications for addiction treatment and public health policies are significant, making this a rapidly evolving area of focus in biopharmaceutical development.
Mar 4, 2026As the biotech job market shows signs of warming, the real effects on various stakeholders—employees, leadership, and prospective job seekers—are nuanced and multifaceted. Executive coach Angela Justice provides insight into these dynamics, highlighting what this shift means for each group.
Mar 4, 2026Merck’s blockbuster cancer drug Keytruda continues to dominate the pharmaceutical sales charts despite the looming end of its exclusivity period. Meanwhile, the rapid market expansion of GLP-1 receptor agonists from Eli Lilly and Novo Nordisk for weight management is shifting the competitive landscape in biopharmaceuticals.
Mar 4, 2026The substantial settlement between Moderna and Roivant highlights the high stakes involved in COVID-19 vaccine intellectual property rights. The resolution avoids prolonged legal battles and potentially sets precedence for future disputes over mRNA-based therapeutics.
Mar 3, 2026The partnership between Boehringer Ingelheim and OSE Immunotherapeutics on the MASH program has come to an end due to underwhelming clinical outcomes in mid-stage trials. As a result, OSE is strategically realigning to concentrate on advancing its lead candidate lusvertikimab, targeting ulcerative colitis, while deprioritizing other assets such as OSE-230 partnered with AbbVie.
Mar 3, 2026The rise of obesity as a critical healthcare challenge has spurred demand for innovative treatments. North Carolina's Holly Springs is emerging as a production hotspot for next-generation GLP-1 obesity therapies, thanks to targeted infrastructure investments and an appealing business environment for biopharmaceutical leaders Amgen and Roche.
Mar 2, 2026In less than a year, BioAtla has doubled its staff reductions, shedding an even greater portion of its workforce. This drastic move signals significant shifts within the company as it evaluates various strategic pathways to sustain its operations and maintain a competitive edge in the dynamic biotech sector.
Mar 2, 2026The FDA's recent approval of Yuviwel introduces a new competitive dynamic in the treatment landscape for achondroplasia. This once-weekly injectable therapy will directly compete with BioMarin's Voxzogo, while BridgeBio pursues its own FGFR3 blocking agent, infigratinib. This landmark approval marks the first weekly dose regimen for achondroplasia medications, signaling potential shifts in patient adherence and market strategies.
Feb 28, 2026This monthly summary provides insights on the patterns of leadership changes within the healthcare industry, exploring how these moves reflect broader shifts in business strategy, workforce management, and responses to dynamic healthcare challenges.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.